Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arrowhead Pharmaceuticals (ARWR) Receivables - Net: 2010-2025

Historic Receivables - Net for Arrowhead Pharmaceuticals (ARWR) over the last 11 years, with Sep 2025 value amounting to $6.8 million.

  • Arrowhead Pharmaceuticals' Receivables - Net was N/A to $6.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.8 million, marking a year-over-year change of. This contributed to the annual value of $6.8 million for FY2025, which is N/A change from last year.
  • As of FY2025, Arrowhead Pharmaceuticals' Receivables - Net stood at $6.8 million, which was up 383.97% from $1.4 million recorded in FY2022.
  • In the past 5 years, Arrowhead Pharmaceuticals' Receivables - Net registered a high of $10.3 million during FY2021, and its lowest value of $1.4 million during FY2022.
  • Over the past 1 years, Arrowhead Pharmaceuticals' median Receivables - Net value was $6.8 million (recorded in 2025), while the average stood at $6.8 million.
  • In the last 5 years, Arrowhead Pharmaceuticals' Receivables - Net spiked by 1,112.17% in 2021 and then tumbled by 86.25% in 2022.
  • Over the past 3 years, Arrowhead Pharmaceuticals' Receivables - Net (Yearly) stood at $10.3 million in 2021, then plummeted by 86.25% to $1.4 million in 2022, then reached $6.8 million in 2025.